Patrick O'Brien

Patrick O'Brien, listed as senior executive, has filed trades across 2 companies (mainly through SEC (Form 4)), most often in Arrowhead Pharmaceuticals, Inc. and Greenlight Capital Re, Ltd. We count 21 filings; the first trade dates from 31 December 2021 and the latest from 23 June 2026.

Sales make up the whole of the open-market record (9 sales, €1.9M). The totals exclude 1 filing filed without an amount. Outside the open market, there are 8 share grants and 2 option exercises. In 2026 alone, the filings show no purchases and 1 sale.

The newest entry dates from 25 June 2026: an open-market sale, in Greenlight Capital Re, Ltd. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. US insiders must file a Form 4 within two business days of a trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.